- Home
- NRO vs BMEA Comparison
NRO vs BMEA Comparison
Compare NRO & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRO
- BMEA
- Stock Information
- Founded
- NRO 2003
- BMEA 2017
- Country
- NRO United States
- BMEA United States
- Employees
- NRO N/A
- BMEA N/A
- Industry
- NRO Finance/Investors Services
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- NRO Finance
- BMEA Health Care
- Exchange
- NRO Nasdaq
- BMEA Nasdaq
- Market Cap
- NRO 187.8M
- BMEA 209.8M
- IPO Year
- NRO N/A
- BMEA 2021
- Fundamental
- Price
- NRO $3.49
- BMEA $3.91
- Analyst Decision
- NRO
- BMEA Buy
- Analyst Count
- NRO 0
- BMEA 13
- Target Price
- NRO N/A
- BMEA $37.25
- AVG Volume (30 Days)
- NRO 239.4K
- BMEA 827.4K
- Earning Date
- NRO 01-01-0001
- BMEA 10-29-2024
- Dividend Yield
- NRO 11.41%
- BMEA N/A
- EPS Growth
- NRO N/A
- BMEA N/A
- EPS
- NRO N/A
- BMEA N/A
- Revenue
- NRO N/A
- BMEA N/A
- Revenue This Year
- NRO N/A
- BMEA N/A
- Revenue Next Year
- NRO N/A
- BMEA N/A
- P/E Ratio
- NRO N/A
- BMEA N/A
- Revenue Growth
- NRO N/A
- BMEA N/A
- 52 Week Low
- NRO $2.51
- BMEA $3.61
- 52 Week High
- NRO $3.45
- BMEA $20.21
- Technical
- Relative Strength Index (RSI)
- NRO 28.62
- BMEA 23.76
- Support Level
- NRO $3.52
- BMEA $5.55
- Resistance Level
- NRO $3.94
- BMEA $6.06
- Average True Range (ATR)
- NRO 0.06
- BMEA 0.49
- MACD
- NRO -0.02
- BMEA -0.08
- Stochastic Oscillator
- NRO 9.19
- BMEA 0.50
About NRO Neuberger Berman Real Estate Securities Income Fund Inc.
NEUBERGER BERMAN REAL ESTATE SECURITIES INCOME FUND INC is a closed-end management investment company that invests mainly in securities issued by real estate companies, including real estate investment trusts (REITs). Its primary objective is to gain high current income with capital appreciation being the second. The fund invests in sectors, such as apartments, Data Centers, Infrastructure REITs, Manufactured Homes, Office, Regional Malls and others.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.